All Updates

All Updates

icon
Filter
Partnerships
Enveric Biosciences enters into licensing agreement with MycoMedica Life Sciences for EVM201 program
Psychedelic Medicine
Nov 12, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Nov 12, 2024

Enveric Biosciences enters into licensing agreement with MycoMedica Life Sciences for EVM201 program

Partnerships

  • Enveric Biosciences, a biotech company focused on neuroplastogen development, has entered a licensing agreement with MycoMedica Life Sciences, a clinical-stage biotechnology company, for its EVM201 program, including drug candidate EB-002.

  • Under the terms of the agreement, MycoMedica receives exclusive global rights to develop EB-002, a synthetic prodrug for treating neuropsychiatric disorders. The deal includes potential milestone payments of up to USD 62 million plus tiered single-digit royalties on future sales, with MycoMedica assuming responsibility for all future development and commercialization.

  • Analyst QuickTake: In July 2024 , Enveric Biosciences secured a US patent for EB-002. This partnership enables Enveric to benefit from MycoMedica's commercialization of EB-002 through milestone payments and royalties, as it advances for neuropsychiatric treatments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.